FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096367061> ?p ?o ?g. }

• W2096367061 endingPage "1206" @default.
• W2096367061 startingPage "1195" @default.
• W2096367061 abstract "Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical studies has synergistic anti-myeloma activity when combined with bortezomib and dexamethasone. We aimed to compare panobinostat, bortezomib, and dexamethasone with placebo, bortezomib, and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.PANORAMA1 is a multicentre, randomised, placebo-controlled, double-blind phase 3 trial of patients with relapsed or relapsed and refractory multiple myeloma who have received between one and three previous treatment regimens. Patients were randomly assigned (1:1) via an interactive web-based and voice response system, stratified by number of previous treatment lines and by previous use of bortezomib, to receive 21 day cycles of placebo or panobinostat (20 mg; on days 1, 3, 5, 8, 10, 12, orally), both in combination with bortezomib (1·3 mg/m(2) on days 1, 4, 8, 11, intravenously) and dexamethasone (20 mg on days 1, 2, 4, 5, 8, 9, 11, 12, orally). Patients, physicians, and the investigators who did the data analysis were masked to treatment allocation; crossover was not permitted. The primary endpoint was progression-free survival (in accordance with modified European Group for Blood and Marrow Transplantation criteria and based on investigators' assessment) and was analysed by intention to treat. The study is ongoing, but no longer recruiting, and is registered at ClinicalTrials.gov, number NCT01023308.768 patients were enrolled between Jan 21, 2010, and Feb 29, 2012, with 387 randomly assigned to panobinostat, bortezomib, and dexamethasone and 381 to placebo, bortezomib, and dexamethasone. Median follow-up was 6·47 months (IQR 1·81-13·47) in the panobinostat group and 5·59 months (2·14-11·30) in the placebo group. Median progression-free survival was significantly longer in the panobinostat group than in the placebo group (11·99 months [95% CI 10·33-12·94] vs 8·08 months [7·56-9·23]; hazard ratio [HR] 0·63, 95% CI 0·52-0·76; p<0·0001). Overall survival data are not yet mature, although at the time of this analysis, median overall survival was 33·64 months (95% CI 31·34-not estimable) for the panobinostat group and 30·39 months (26·87-not estimable) for the placebo group (HR 0·87, 95% CI 0·69-1·10; p=0·26). The proportion of patients achieving an overall response did not differ between treatment groups (235 [60·7%, 95% CI 55·7-65·6] for panobinostat vs 208 [54·6%, 49·4-59·7] for placebo; p=0·09); however, the proportion of patients with a complete or near complete response was significantly higher in the panobinostat group than in the placebo group (107 [27·6%, 95% CI 23·2-32·4] vs 60 [15·7%, 12·2-19·8]; p=0·00006). Minimal responses were noted in 23 (6%) patients in the panobinostat group and in 42 (11%) in the placebo group. Median duration of response (partial response or better) was 13·14 months (95% CI 11·76-14·92) in the panobinostat group and 10·87 months (9·23-11·76) in the placebo group, and median time to response (partial response or better) was 1·51 months (1·41-1·64) in the panobinostat group and 2·00 months (1·61-2·79) in the placebo group. Serious adverse events were reported in 228 (60%) of 381 patients in the panobinostat group and 157 (42%) of 377 patients in the placebo group. Common grade 3-4 laboratory abnormalities and adverse events (irrespective of association with study drug) included thrombocytopenia (256 [67%] in the panobinostat group vs 118 [31%] in the placebo group), lymphopenia (202 [53%] vs 150 [40%]), diarrhoea (97 [26%] vs 30 [8%]), asthenia or fatigue (91 [24%] vs 45 [12%]), and peripheral neuropathy (67 [18%] vs 55 [15%]).Our results suggest that panobinostat could be a useful addition to the treatment armamentarium for patients with relapsed or relapsed and refractory multiple myeloma. Longer follow up will be necessary to determine whether there is any effect on overall survival.Novartis Pharmaceuticals." @default.
• W2096367061 created "2016-06-24" @default.
• W2096367061 creator A5000607466 @default.
• W2096367061 creator A5000672264 @default.
• W2096367061 creator A5001314912 @default.
• W2096367061 creator A5002857933 @default.
• W2096367061 creator A5003468777 @default.
• W2096367061 creator A5003689547 @default.
• W2096367061 creator A5009117622 @default.
• W2096367061 creator A5009336240 @default.
• W2096367061 creator A5009864755 @default.
• W2096367061 creator A5011687418 @default.
• W2096367061 creator A5011827756 @default.
• W2096367061 creator A5016360607 @default.
• W2096367061 creator A5017804632 @default.
• W2096367061 creator A5018685925 @default.
• W2096367061 creator A5020989412 @default.
• W2096367061 creator A5023276777 @default.
• W2096367061 creator A5025191470 @default.
• W2096367061 creator A5027328800 @default.
• W2096367061 creator A5030583882 @default.
• W2096367061 creator A5031837957 @default.
• W2096367061 creator A5032960925 @default.
• W2096367061 creator A5033439690 @default.
• W2096367061 creator A5033573338 @default.
• W2096367061 creator A5034186877 @default.
• W2096367061 creator A5035748455 @default.
• W2096367061 creator A5038879690 @default.
• W2096367061 creator A5043221610 @default.
• W2096367061 creator A5043526996 @default.
• W2096367061 creator A5043829360 @default.
• W2096367061 creator A5044268319 @default.
• W2096367061 creator A5049230560 @default.
• W2096367061 creator A5051903959 @default.
• W2096367061 creator A5065104304 @default.
• W2096367061 creator A5067657650 @default.
• W2096367061 creator A5068293508 @default.
• W2096367061 creator A5068614681 @default.
• W2096367061 creator A5073352185 @default.
• W2096367061 creator A5073829136 @default.
• W2096367061 creator A5074020738 @default.
• W2096367061 creator A5077318648 @default.
• W2096367061 creator A5077897003 @default.
• W2096367061 creator A5081233146 @default.
• W2096367061 creator A5086416072 @default.
• W2096367061 creator A5088242526 @default.
• W2096367061 creator A5089922903 @default.
• W2096367061 date "2014-10-01" @default.
• W2096367061 modified "2023-10-01" @default.
• W2096367061 title "Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial" @default.
• W2096367061 cites W1969648097 @default.
• W2096367061 cites W1978377409 @default.
• W2096367061 cites W1992538067 @default.
• W2096367061 cites W2021954218 @default.
• W2096367061 cites W2048722552 @default.
• W2096367061 cites W2052169053 @default.
• W2096367061 cites W2066800926 @default.
• W2096367061 cites W2070790769 @default.
• W2096367061 cites W2079167171 @default.
• W2096367061 cites W2084594085 @default.
• W2096367061 cites W2089311432 @default.
• W2096367061 cites W2096207943 @default.
• W2096367061 cites W2099262276 @default.
• W2096367061 cites W2104244233 @default.
• W2096367061 cites W2106333492 @default.
• W2096367061 cites W2108235071 @default.
• W2096367061 cites W2124560610 @default.
• W2096367061 cites W2127760782 @default.
• W2096367061 cites W2132880072 @default.
• W2096367061 cites W2136541422 @default.
• W2096367061 cites W2141247841 @default.
• W2096367061 cites W2150878522 @default.
• W2096367061 cites W2152124092 @default.
• W2096367061 cites W2168980644 @default.
• W2096367061 cites W2169183166 @default.
• W2096367061 cites W2171585059 @default.
• W2096367061 doi "https://doi.org/10.1016/s1470-2045(14)70440-1" @default.
• W2096367061 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25242045" @default.
• W2096367061 hasPublicationYear "2014" @default.
• W2096367061 type Work @default.
• W2096367061 sameAs 2096367061 @default.
• W2096367061 citedByCount "672" @default.
• W2096367061 countsByYear W20963670612014 @default.
• W2096367061 countsByYear W20963670612015 @default.
• W2096367061 countsByYear W20963670612016 @default.
• W2096367061 countsByYear W20963670612017 @default.
• W2096367061 countsByYear W20963670612018 @default.
• W2096367061 countsByYear W20963670612019 @default.
• W2096367061 countsByYear W20963670612020 @default.
• W2096367061 countsByYear W20963670612021 @default.
• W2096367061 countsByYear W20963670612022 @default.
• W2096367061 countsByYear W20963670612023 @default.
• W2096367061 crossrefType "journal-article" @default.
• W2096367061 hasAuthorship W2096367061A5000607466 @default.
• W2096367061 hasAuthorship W2096367061A5000672264 @default.
• W2096367061 hasAuthorship W2096367061A5001314912 @default.
• W2096367061 hasAuthorship W2096367061A5002857933 @default.
• W2096367061 hasAuthorship W2096367061A5003468777 @default.

• next